1.08
-0.08(-6.90%)
Currency In USD
| Previous Close | 1.16 |
| Open | 1.14 |
| Day High | 1.14 |
| Day Low | 1.02 |
| 52-Week High | 1.87 |
| 52-Week Low | 0.54 |
| Volume | 1.1M |
| Average Volume | 202,979 |
| Market Cap | 11.52M |
| PE | -0.59 |
| EPS | -1.82 |
| Moving Average 50 Days | 0.97 |
| Moving Average 200 Days | 0.88 |
| Change | -0.08 |
If you invested $1000 in Biofrontera Inc. (BFRI) since IPO date, it would be worth $12.24 as of November 08, 2025 at a share price of $1.08. Whereas If you bought $1000 worth of Biofrontera Inc. (BFRI) shares 3 years ago, it would be worth $58.06 as of November 08, 2025 at a share price of $1.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further bolsters our cash position, which is expected to fun
Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025
GlobeNewswire Inc.
Nov 06, 2025 9:01 PM GMT
WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial resul
Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG
GlobeNewswire Inc.
Oct 23, 2025 12:45 PM GMT
Biofrontera Inc. acquires full U.S. rights to Ameluz® and RhodoLED®, including New Drug Application and associated patents, from former parent Biofrontera AG.New earnout structure reduces payment rate to 12%–15% of U.S. net sales from 25%–35%.Closing